GI Dynamics today announced the results of a study of its EndoBarrier system that met efficacy and safety endpoints.
Boston-based GI Dynamics designed its EndoBarrier endoscopically delivered device therapy as a non-surgical, alternative treatment for type 2 diabetes and obesity for patients who do not have adequate control of their conditions through their current medication and lifestyle.
According to a news release, data from the study were presented at the annual Digestive Disease Week (DDW) conference last month. Results from the multicenter, randomized, sham-controlled trial of a duodenal jejunal bypass liner (DJBL) for treating type 2 diabetes mellitus were presented by Dr. Christopher C. Thompson, Professor at Harvard Medical School and Director of Endoscopy at Brigham and Women’s Hospital.
The study enrolled patients from 2013 to 2015 and included subjects randomized to DJBL and a sham procedure with moderate-intensity lifestyle interventi…